抗PD-1疗法与皮肤病延迟发作有关

2018-07-28 MedSci MedSci原创

一项最新研究表明,抗PD-1治疗的副作用可在治疗后3年以上显现。

PD-1是由活化的T细胞表达的细胞表面免疫检查点受体,并且对免疫系统抵抗疾病的能力至关重要。抗PD-1免疫疗法关闭此检查点,使T细胞继续工作。该方法用于多种癌症,包括黑素瘤和肺癌。大约40%的接受抗PD-1免疫疗法的患者产生了自身免疫性皮肤病,如牛皮癣,湿疹和狼疮样反应。

一项最新研究表明,抗PD-1治疗的副作用可在治疗后3年以上显现。宾夕法尼亚大学佩雷​​尔曼医学院的皮肤科医生汇总了2014年至2018年在宾夕法尼亚大学就诊的17名患者的数据。每位患者都患有转移性疾病,并对其皮肤状况进行了活组织检查。12例患有黑色素瘤,2例患有肾细胞癌,3例患有鳞状细胞癌。研究小组发现,17例患者中有12例在开始用抗PD-1药物(pembrolizumabnivolumab)治疗后约3个月出现皮肤病。治疗后出现皮肤病的最短时间为两周,最长时间为38个月。5名患者在不再服用该药后出现副作用。

该研究的高级作者,皮肤病学助理教授Emily Y. Chu博士说:这些治疗方法对皮肤的影响有很好的记录,但对这些不良事件的出现时间的研究相对较少,这是至关重要的这一点,因为这项研究既可以告诉医生应该注意什么,也可以帮助他们向患者提出预期的建议


原始出处:

https://www.europeanpharmaceuticalreview.com/news/77477/anti-pd-1-skin-disease/

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826109, encodeId=5bb1182610972, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 25 12:42:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336324, encodeId=0be7336324ba, content=嗯嗯,学习学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:15 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334729, encodeId=f1f2334e297b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Sat Jul 28 15:02:31 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334711, encodeId=cd38334e1108, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:16:08 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826109, encodeId=5bb1182610972, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 25 12:42:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336324, encodeId=0be7336324ba, content=嗯嗯,学习学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:15 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334729, encodeId=f1f2334e297b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Sat Jul 28 15:02:31 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334711, encodeId=cd38334e1108, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:16:08 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-08-04 liumin1987

    嗯嗯,学习学习。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826109, encodeId=5bb1182610972, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 25 12:42:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336324, encodeId=0be7336324ba, content=嗯嗯,学习学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:15 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334729, encodeId=f1f2334e297b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Sat Jul 28 15:02:31 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334711, encodeId=cd38334e1108, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:16:08 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-07-28 小小小麦兜

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826109, encodeId=5bb1182610972, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Feb 25 12:42:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336324, encodeId=0be7336324ba, content=嗯嗯,学习学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sat Aug 04 10:58:15 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334729, encodeId=f1f2334e297b, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/f3d88083d8829740786bed95c22464d1/e325f3af93bb747a620d16c209094d69.jpg, createdBy=9efb2014947, createdName=小小小麦兜, createdTime=Sat Jul 28 15:02:31 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334711, encodeId=cd38334e1108, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 28 11:16:08 CST 2018, time=2018-07-28, status=1, ipAttribution=)]
    2018-07-28 医者仁心5538

    学习了

    0

相关资讯

CLIN CANCER RES:CD103+肿瘤定植CD8+T细胞与黑色素瘤患者接受抗PD-1治疗预后改善有关

免疫检查点抑制疗法为肿瘤治疗带来了革命。但是只有不到一半的接受治疗的患者出现持续缓解。由于缺少对启动抗肿瘤免疫反应的细胞特征的理解,如何改善治疗效果也一直并不明确。CLIN CANCER RES近期发表了一篇文章研究这一问题。

BMS的PD-1明星单抗Opdivo引领其第二季度销售额达57亿美元

BMS在第二季度中,几乎所有的主要产品都超过销售预期,销售额达57亿美元,这一数字超过市场预期的54.8亿美元。每股收益达到1.01美元,打破了华尔街87美分的预测。

Nat Immunol:PD-1/PD-L1不响应机制被揭密,NK细胞其核心作用

本周二,国际顶级期刊《自然免疫学》刊登了中国科学技术大学田志刚、孙汭(rui)教授课题组的重要研究成果[2]。他们的研究成果在一定程度上解释了为什么有些患者对目前的免疫检查点抑制剂治疗不响应;更重要的是,他们的研究成果有望大幅扩大免疫检查点抑制剂适用的患者群体。本研究的第一作者是张清博士。 伴随研究论文同期发表的评论性文章给予该研究非常高的评价,“检查点抑制剂:自然杀伤(

Cell Rep:大开眼界!肿瘤细胞竟是这样躲过免疫治疗的!

目前,以PD-1/PD-L1抑制剂为主的免疫疗法已成为肿瘤治疗领域的绝对热门,但是,PD-1 /PD-L1抑制剂在不同类型肿瘤病人中应用后,其效果却因人而异。科学家们曾认为这是受制于患者肿瘤细胞PD-L1的表达水平,然而,随着对PD-1 /PD-L1抑制剂疗法的深入研究,研究人员发现部分患者即使表达了高水平的PD-L1,PD-1 /PD-L1抑制剂仍无法有效治疗肿瘤。这是为什么呢?

百济神州公布其PD-1抗体Tislelizumab治疗霍奇金淋巴瘤中的关键性临床试验初步结果

百济神州Biogene(纳斯达克股票代码:BGNE)是一家处于商业阶段的生物医药公司,专注于开发和商业化治疗癌症的创新分子靶向药物和肿瘤免疫药物。近日公司公布了其PD-1抗体Tslelizumab治疗复发/难治性经典霍奇金淋巴瘤(R/R cHL)中国患者的关键性2期临床试验独立审查的初步结果。

PD-1单抗Keytruda单一疗法显著延长头颈癌患者生存期

默沙东(MSD)的Keytruda作为单一疗法,用于PD-L1阳性的复发或转移性头颈部鳞状细胞癌(HNSCC)患者的一线治疗时,显着延长了患者的总体存活率。